Total Payments
$886.26
2024 Payments
$90.12
Companies
15
Transactions
24
Medicare Patients
2,106
Medicare Billing
$117,108
Payment Breakdown by Category
Consulting$450.00 (50.8%)
Food & Beverage$436.26 (49.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $450.00 | 1 | 50.8% |
| Food and Beverage | $436.26 | 23 | 49.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| 3M Company | $450.00 | 1 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $59.64 | 3 | $0 (2024) |
| Lilly USA, LLC | $56.24 | 3 | $0 (2023) |
| GENZYME CORPORATION | $51.23 | 3 | $0 (2023) |
| ABBVIE INC. | $42.76 | 2 | $0 (2024) |
| Incyte Corporation | $42.12 | 2 | $0 (2023) |
| Janssen Biotech, Inc. | $37.20 | 2 | $0 (2023) |
| LEO Pharma Inc. | $27.77 | 1 | $0 (2024) |
| DERMIRA, INC. | $21.69 | 1 | $0 (2019) |
| Organon Llc | $19.78 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $90.12 | 4 | LEO Pharma Inc. ($27.77) |
| 2023 | $170.97 | 10 | Lilly USA, LLC ($39.87) |
| 2022 | $87.96 | 4 | Incyte Corporation ($25.84) |
| 2021 | $30.42 | 2 | GENZYME CORPORATION ($18.92) |
| 2020 | $35.10 | 2 | Ortho Dermatologics, a division of Bausch Health US, LLC ($19.77) |
| 2019 | $21.69 | 1 | DERMIRA, INC. ($21.69) |
| 2018 | $450.00 | 1 | 3M Company ($450.00) |
All Payment Transactions
24 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/03/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $27.77 | General |
| Category: DERMATOLOGY | ||||||
| 09/30/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $25.00 | General |
| Category: Immunology | ||||||
| 09/05/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $17.57 | General |
| Category: IMMUNOLOGY | ||||||
| 06/17/2024 | Organon Llc | HADLIMA (Drug) | Food and Beverage | In-kind items and services | $19.78 | General |
| Category: ADALIMUMAB-BWWD | ||||||
| 12/11/2023 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $14.08 | General |
| Category: Immunology | ||||||
| 11/20/2023 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $16.28 | General |
| Category: Dermatology | ||||||
| 10/23/2023 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Food and Beverage | In-kind items and services | $16.57 | General |
| Category: Immunology | ||||||
| 08/01/2023 | Mylan Institutional Inc. | — | Food and Beverage | In-kind items and services | $16.95 | General |
| 07/24/2023 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $17.85 | General |
| Category: Immunology | ||||||
| 07/11/2023 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $16.70 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 06/12/2023 | Lilly USA, LLC | TALTZ (Drug), OLUMIANT | Food and Beverage | In-kind items and services | $22.02 | General |
| Category: Immunology | ||||||
| 04/25/2023 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $12.91 | General |
| Category: DERMATOLOGY | ||||||
| 04/24/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: Immunology | ||||||
| 01/09/2023 | Janssen Biotech, Inc. | REMICADE (Biological), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $21.87 | General |
| Category: Immunology | ||||||
| 11/17/2022 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $20.56 | General |
| Category: Immunology | ||||||
| 10/12/2022 | ABBVIE INC. | HUMIRA (Biological) | Food and Beverage | In-kind items and services | $25.19 | General |
| Category: IMMUNOLOGY | ||||||
| 10/03/2022 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $16.37 | General |
| Category: Immunology | ||||||
| 03/09/2022 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $25.84 | General |
| Category: Dermatology | ||||||
| 08/19/2021 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $18.92 | General |
| Category: Immunology | ||||||
| 01/13/2021 | SUN PHARMACEUTICAL INDUSTRIES INC. | Absorica LD (Drug), Ultravate | Food and Beverage | In-kind items and services | $11.50 | General |
| Category: Dermatology | ||||||
| 11/18/2020 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $15.33 | General |
| Category: Immunology | ||||||
| 10/28/2020 | Ortho Dermatologics, a division of Bausch Health US, LLC | ARAZLO (Drug) | Food and Beverage | In-kind items and services | $19.77 | General |
| Category: DERMATOLOGY | ||||||
| 06/21/2019 | DERMIRA, INC. | — | Food and Beverage | In-kind items and services | $21.69 | General |
| 10/01/2018 | 3M Company | Codran Tape (Drug) | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| Category: Topical steroid | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 615 | 1,055 | $138,471 | $33,474 |
| 2022 | 8 | 586 | 924 | $105,874 | $31,156 |
| 2021 | 7 | 538 | 1,002 | $93,620 | $30,767 |
| 2020 | 8 | 367 | 547 | $62,695 | $21,711 |
Total Patients
2,106
Total Services
3,528
Medicare Billing
$117,108
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 140 | 150 | $34,268 | $8,629 | 25.2% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 96 | 103 | $30,216 | $8,216 | 27.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 108 | 127 | $23,155 | $4,347 | 18.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 62 | 62 | $16,289 | $4,008 | 24.6% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 39 | 43 | $10,971 | $2,874 | 26.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 84 | 450 | $11,095 | $2,140 | 19.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 47 | 56 | $7,781 | $2,016 | 25.9% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 26 | 26 | $4,391 | $1,215 | 27.7% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 13 | 38 | $304.30 | $29.18 | 9.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 152 | 178 | $28,780 | $10,585 | 36.8% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 70 | 72 | $17,500 | $5,778 | 33.0% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 116 | 130 | $20,785 | $4,746 | 22.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 79 | 87 | $8,759 | $2,826 | 32.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 38 | 38 | $9,166 | $2,675 | 29.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 82 | 370 | $12,104 | $1,800 | 14.9% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 21 | 21 | $4,378 | $1,562 | 35.7% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 28 | 28 | $4,403 | $1,184 | 26.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 130 | 167 | $21,512 | $10,166 | 47.3% |
| 17000 | Destruction of skin growth | Office | 2021 | 109 | 155 | $23,149 | $5,909 | 25.5% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 59 | 68 | $13,804 | $5,252 | 38.0% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 101 | 116 | $9,083 | $3,809 | 41.9% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 33 | 37 | $6,534 | $2,174 | 33.3% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 84 | 437 | $15,295 | $1,988 | 13.0% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 22 | 22 | $4,243 | $1,470 | 34.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 119 | 120 | $22,968 | $9,882 | 43.0% |
About Dr. Scott Ross, MD
Dr. Scott Ross, MD is a Dermatology healthcare provider based in Whitehall, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/05/2005. The National Provider Identifier (NPI) number assigned to this provider is 1417944349.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Scott Ross, MD has received a total of $886.26 in payments from pharmaceutical and medical device companies, with $90.12 received in 2024. These payments were reported across 24 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($450.00).
As a Medicare-enrolled provider, Ross has provided services to 2,106 Medicare beneficiaries, totaling 3,528 services with total Medicare billing of $117,108. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Other Specialties Dermatology, Dermatology
- Location Whitehall, WI
- Active Since 10/05/2005
- Last Updated 04/30/2025
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1417944349
Products in Payments
- Codran Tape (Drug) $450.00
- DUPIXENT (Biological) $67.93
- Sotyktu (Drug) $59.64
- TALTZ (Drug) $56.24
- OPZELURA (Drug) $42.12
- ADBRY (Biological) $27.77
- HUMIRA (Biological) $25.19
- REMICADE (Biological) $21.87
- HADLIMA (Drug) $19.78
- ARAZLO (Drug) $19.77
- SKYRIZI (Biological) $17.57
- TREMFYA (Drug) $15.33
- VTAMA (Drug) $12.91
- Absorica LD (Drug) $11.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.